Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

NCT: NCT07785102 · NOT_YET_RECRUITING

NCT IDNCT07785102
StatusNOT_YET_RECRUITING
Start Date2026-09-01
Completion2027-03-31
SponsorMclean Hospital (OTHER)
First posted
Last updated

Brief Summary

In this pilot study, investigators aim to combine D-cycloserine, lurasidone, and single-day repeated intermittent Theta Burst Stimulation (iTBS) to preliminarily assess clinical improvement in an open-label cohort and monitor for adverse events over a 6-week follow-up period.

Frequently Asked Questions

What is Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101?

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101 is a clinical trial registered under NCT07785102. Current status: NOT_YET_RECRUITING.

What is the status of NCT07785102?

The current status of NCT07785102 (Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101) is: NOT_YET_RECRUITING.

When did Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101 start?

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101 started on 2026-09-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.